FI114483B - Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta - Google Patents

Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta Download PDF

Info

Publication number
FI114483B
FI114483B FI20010323A FI20010323A FI114483B FI 114483 B FI114483 B FI 114483B FI 20010323 A FI20010323 A FI 20010323A FI 20010323 A FI20010323 A FI 20010323A FI 114483 B FI114483 B FI 114483B
Authority
FI
Finland
Prior art keywords
deletion
adrenoceptor
amino acids
genotype
hypertension
Prior art date
Application number
FI20010323A
Other languages
English (en)
Finnish (fi)
Other versions
FI20010323A0 (sv
FI20010323A (sv
Inventor
Jukka T Salonen
Original Assignee
Jurilab Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jurilab Ltd Oy filed Critical Jurilab Ltd Oy
Publication of FI20010323A0 publication Critical patent/FI20010323A0/sv
Priority to FI20010323A priority Critical patent/FI114483B/sv
Priority to EP02711915A priority patent/EP1368454A1/en
Priority to CNA028086015A priority patent/CN1522303A/zh
Priority to DE0001368454T priority patent/DE02711915T1/de
Priority to AU2002231847A priority patent/AU2002231847A1/en
Priority to JP2002566324A priority patent/JP2004528830A/ja
Priority to PCT/FI2002/000113 priority patent/WO2002066617A1/en
Priority to US10/077,870 priority patent/US7029849B2/en
Publication of FI20010323A publication Critical patent/FI20010323A/sv
Application granted granted Critical
Publication of FI114483B publication Critical patent/FI114483B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (6)

1. Förfarande för att detektera en risk för förhöjt blodtryck hos en individ genom att bestämma strukturen av allelen som kodar variant-a2B-adrenoceptor, dvs genom att bestämma huruvida människans a2B-adrenoceptor-genotyp hos 15 nämnda individ är av deletion/deletion (D/D)-typ, enligt vilket förfarande man medelst ett test bestämmer i ett biologiskt prov frän individen som skall undersökas, närvaron av en insertion/insertion (I/I)-, deletion/insertion (D/I)- ‘. eller deletion/deletion (D/D)- a2B-adrenoceptors-genotyp, varvid närvaron av en , ·, D/D-genotyp betyder en risk för utveckling av förhöjt blodtryck hos individen, ·*·': 20 varvid nämnda deletion (D) hänför sig tili en genotyp, i vilken allelen kodar ett : : vanant-a2B-adrenoceptorprotein, vilken uppvisar en deletion av tre glutamater, '! ‘: aminosyroma 307-309, i ett glutaminsyrarepetitionselement omfatande 12 « · * :· glutamater, aminosyroma 298-309, i en sur följd av 18 aminosyror, 294-311, i receptorpolypeptidens 3. intracellulära ögla, och nämnda insertion (I) hänvisar ! ί ’ 25 tili en genotyp, i vilken allelen kodar sagda (X2B-adrenoceptorprotein utan a t k ' · · * nämnda deletion.
',,,! 2. Förfarande enligt patentkravet 1, kännetecknat därav, att testet är ett DNA-test. •': 30
3. Förfarande enligt patentkravet 1, kännetecknat därav, att allelens struktur bestäms genom användning av en polymeraskedjereaktion. 114483
4. Förfarande enligt patentkravet 1, kännetecknat därav, att genomt DNA isoleras frän ett blodprov frän individen.
5 5. Förfarande enligt patentkravet 1, kännetecknat därav, att det baserar sig pä en fangstprob som omfattar ensträngat cDNA, varvid sagda DNA-sekvens är cDNA som omfattar en nukleotidsekvens som kodar ett variant-a2B-adreno-ceptorprotein vilken uppvisar en deletion av tre glutamater, aminosyroma 307-309, i ett glutaminsyrarepetitionselement omfattande 12 glutamater, amino-10 syroma 298-309, i en sur följd av 18 aminosyror, 294-311, i receptorpoly- peptidens 3. intracellulära ögla.
6. Förfarande enligt patentkravet 1, kännetecknat därav, att det baserar sig pä en fangstprob som omfattar ensträngat cDNA som motsvarar a2B-adrenoceptom 15 utan den i patentkravet 1 definierade deletionen. I I t 1 114483 SEQUENCE LISTING <110> Salonen, Jukka T <120> Method for detecting a risk of hypertension and uses thereof <130> Alpha-2B-AR variant <140> <141> <160> 10 <170> Patentin Ver. 2.1 <210> 1 <211> 1344 <212> DNA <213> Homo sapiens <220> <221> CDS <222> (1)..(1341) <223> Coding sequence for variant human alpha-2B-adrenoceptor protein <400> 1 atg gac cac cag gac ccc tac tcc gtg cag gcc aca gcg gcc ata gcg 48 Met Asp His Gin Asp Pro Tyr Ser Val Gin Ala Thr Ala Ala lie Ala 15 10 15 gcg gcc ate acc ttc etc att etc ttt acc ate ttc ggc aac get ctg 96 Ala Ala lie Thr Phe Leu lie Leu Phe Thr lie Phe Gly Asn Ala Leu 20 25 30 • · • gtc ate ctg get gtg ttg acc age ege teg ctg ege gcc cct cag aac 144 ·. .* Val lie Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gin Asn : \: 35 40 45 "··’ ctg ttc ctg gtg teg ctg gcc gcc gcc gac ate ctg gtg gcc aeg etc 192 ·;··· Leu Phe Leu Val Ser Leu Ala Ala Ala Asp lie Leu Val Ala Thr Leu 50 55 60 • * * ate ate cct ttc teg ctg gcc aac gag ctg ctg ggc tac tgg tac ttc 240 lie lie Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe 65 70 75 80 • egg ege aeg tgg tgc gag gtg tac ctg gcg etc gac gtg etc ttc tgc 288 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys : 85 90 95 ; acc teg tcc ate gtg cac ctg tgc gcc ate age ctg gac ege tac tgg 336 'C Thr Ser Ser lie Val His Leu Cys Ala lie Ser Leu Asp Arg Tyr Trp loo 105 no « t *; * * f gcc gtg age ege gcg ctg gag tae aac tcc aag ege acc ccg ege ege 384 Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg 115 120 125 ate aag tgc ate ate etc act gtg tgg etc ate gcc gcc gtc ate teg 432 lie Lys Cys lie lie Leu Thr Val Trp Leu lie Ala Ala Val lie Ser 130 135 140 2 114483 ctg ccg ccc etc ate tae aag ggc gac cag ggc ccc cag ccg ege ggg 480 Leu Pro Pro Leu lie Tyr Lys Gly Asp Gin Gly Pro Gin Pro Arg Gly 145 150 155 160 ege ccc cag tgc aag etc aac cag gag gee tgg tae ate ctg gee tee 528 Arg Pro Gin Cys Lys Leu Asn Gin Glu Ala Trp Tyr lie Leu Ala Ser 165 170 175 age ate gga tet ttc ttt get cct tgc etc ate atg ate ett gtc tae 576 Ser lie Gly Ser Phe Phe Ala Pro Cys Leu lie Met lie Leu Val Tyr 180 185 190 ctg ege ate tae ctg ate gee aaa ege age aac ege aga ggt ccc agg 624 Leu Arg lie Tyr Leu lie Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg 195 200 205 gee aag ggg ggg cct ggg cag ggt gag tee aag cag ccc ega ccc gac 672 Ala Lys Gly Gly Pro Gly Gin Gly Glu Ser Lys Gin Pro Arg Pro Asp 210 215 220 cat ggt ggg get ttg gee tea gee aaa ctg cca gee ctg gee tet gtg 720 His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Val 225 230 235 240 get tet gee aga gag gtc aac gga cac teg aag tee act ggg gag aag 768 Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys 245 250 255 gag gag ggg gag ace cct gaa gat act ggg ace egg gee ttg cca ccc 816 Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro 260 265 270 *, \ agt tgg get gee ett ccc aac tea ggc cag ggc cag aag gag ggt gtt 864 ’/· Ser Trp Ala Ala Leu Pro Asn Ser Gly Gin Gly Gin Lys Glu Gly Val ··.’ 275 280 285 ·”*. tgt ggg gca tet cca gag gat gaa get gaa gag gag gaa gag gag gag 912 ···" Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu Glu ·;·· 290 295 300 • J gag gag tgt gaa ccc cag gca gtg cca gtg tet ccg gee tea get tgc 960 Glu Glu Cys Glu Pro Gin Ala Val Pro Val Ser Pro Ala Ser Ala Cys 305 310 315 320 ' '· age ccc ccg ctg cag cag cca cag ggc tee egg gtg ctg gee acc eta 1008 Ser Pro Pro Leu Gin Gin Pro Gin Gly Ser Arg Val Leu Ala Thr Leu 325 330 335 ; · cgt ggc cag gtg etc ctg ggc agg ggc gtg ggt get ata ggt ggg cag 1056 ; ; Arg Gly Gin Val Leu Leu Gly Arg Gly Val Gly Ala lie Gly Gly Gin 340 345 350 * > * ’ tgg tgg cgt ega egg geg cag ctg acc egg gag aag ege ttc acc ttc 1104 Trp Trp Arg Arg Arg Ala Gin Leu Thr Arg Glu Lys Arg Phe Thr Phe 355 360 365 gtg ctg get gtg gtc att ggc gtt ttt gtg etc tgc tgg ttc ccc ttc 1152 Val Leu Ala Val Val lie Gly Val Phe Val Leu Cys Trp Phe Pro Phe 370 375 380 3 114483 ttc ttc age tae age ctg ggc gee ate tgc ccg aag cac tgc aag gtg 1200 Phe Phe Ser Tyr Ser Leu Gly Ala lie Cys Pro Lys His Cys Lys Val 385 390 395 400 ccc cat ggc etc ttc cag ttc ttc ttc tgg ate ggc tae tgc aac age 1248 Pro His Gly Leu Phe Gin Phe Phe Phe Trp lie Gly Tyr Cys Asn Ser 405 410 415 tea ctg aac cct gtt ate tae ace ate ttc aac cag gac ttc ege cgt 1296 Ser Leu Asn Pro Val lie Tyr Thr lie Phe Asn Gin Asp Phe Arg Arg 420 425 430 gee ttc egg agg ate ctg tgc ege ccg tgg ace cag aeg gee tgg tga 1344 Ala Phe Arg Arg lie Leu Cys Arg Pro Trp Thr Gin Thr Ala Trp 435 440 445 <210> 2 <211> 447 <212> PRT <213> Homo sapiens <400> 2 Met Asp His Gin Asp Pro Tyr Ser Val Gin Ala Thr Ala Ala lie Ala 1 5 10 15 Ala Ala lie Thr Phe Leu lie Leu Phe Thr lie Phe Gly Asn Ala Leu 20 25 30 Val lie Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gin Asn 35 40 45 ;·' : Leu Phe Leu Val Ser Leu Ala Ala Ala Asp lie Leu Val Ala Thr Leu \ 50 55 60 ·*.·. lie lie Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe ·' ·' 65 70 75 80 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys 85 90 95 Thr Ser Ser lie Val His Leu Cys Ala lie Ser Leu Asp Arg Tyr Trp 100 105 110 Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg 115 120 125 • lie Lys Cys lie lie Leu Thr Val Trp Leu lie Ala Ala Val lie Ser :*·.· 130 135 140 ·' ! Leu Pro Pro Leu lie Tyr Lys Gly Asp Gin Gly Pro Gin Pro Arg Gly 145 150 155 160 * t Arg Pro Gin Cys Lys Leu Asn Gin Glu Ala Trp Tyr lie Leu Ala Ser :·*: 165 170 175 Ser lie Gly Ser Phe Phe Ala Pro Cys Leu lie Met lie Leu Val Tyr 180 185 190 Leu Arg lie Tyr Leu lie Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg 195 200 205 4 114483 Ala Lys Gly Gly Pro Gly Gin Gly Glu Ser Lys Gin Pro Arg Pro Asp 210 215 220 His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Vai 225 230 235 240 Ala Ser Ala Arg Glu Vai Asn Gly His Ser Lys Ser Thr Gly Glu Lys 245 250 255 Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro 260 265 270 Ser Trp Ala Ala Leu Pro Asn Ser Gly Gin Gly Gin Lys Glu Gly Vai 275 280 285 Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu Glu 290 295 300 Glu Glu Cys Glu Pro Gin Ala Vai Pro Vai Ser Pro Ala Ser Ala Cys 305 310 315 320 Ser Pro Pro Leu Gin Gin Pro Gin Gly Ser Arg Vai Leu Ala Thr Leu 325 330 335 Arg Gly Gin Vai Leu Leu Gly Arg Gly Vai Gly Ala Ile Gly Gly Gin 340 345 350 Trp Trp Arg Arg Arg Ala Gin Leu Thr Arg Glu Lys Arg Phe Thr Phe 355 360 365 Vai Leu Ala Vai Vai Ile Gly Vai Phe Vai Leu Cys Trp Phe Pro Phe 370 375 380 . *. Phe Phe Ser Tyr Ser Leu Gly Ala Ile Cys Pro Lys His Cys Lys Vai •'.‘•I 385 390 395 400 • Pro His Gly Leu Phe Gin Phe Phe Phe Trp Ile Gly Tyr Cys Asn Ser ;·*. 405 410 415 ' Ϊ * *: Ser Leu Asn Pro Vai Ile Tyr Thr Ile Phe Asn Gin Asp Phe Arg Arg 420 425 430 Ala Phe Arg Arg Ile Leu Cys Arg Pro Trp Thr Gin Thr Ala Trp 435 440 445 ’· ’·* <210> 3 <211> 1353 <212> DNA ;’· j <213> Homo sapiens <220> <221> CDS <222> (1)..(1350) <223> Coding sequence for human alpha-2B-adrenoceptor protein <400> 3 atg gac cac cag gac ccc tac tcc gtg cag gcc aca gcg gcc ata gcg 48 Met Asp His Gin Asp Pro Tyr Ser Val Gin Ala Thr Ala Ala lie Ala 15 10 15 5 114483 gcg gcc ate acc ttc etc att etc ttt acc atc ttc ggc aac get ctg 96 Ala Ala Ile Thr Phe Leu Ile Leu Phe Thr Ile Phe Gly Asn Ala Leu 20 25 30 gtc atc ctg get gtg ttg acc age cge teg ctg cgc gee eet cag aac 144 Vai Ile Leu Ala Vai Leu Thr Ser Arg Ser Leu Arg Ala Pro Gin Asn 35 40 45 ctg ttc ctg gtg teg ctg gee gee gee gae ate ctg gtg gee aeg etc 192 Leu Phe Leu Vai Ser Leu Ala Ala Ala Asp Ile Leu Vai Ala Thr Leu 50 55 60 ate ate eet ttc teg ctg gee aac gag ctg ctg ggc tae tgg tae ttc 240 Ile Ile Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe 65 70 75 80 cgg cgc aeg tgg tgc gag gtg tae ctg gcg etc gae gtg etc ttc tgc 288 Arg Arg Thr Trp Cys Glu Vai Tyr Leu Ala Leu Asp Vai Leu Phe Cys 85 90 95 acc tcg tee atc gtg cac ctg tgc gcc ate age ctg gae cgc tae tgg 336 Thr Ser Ser Ile Vai His Leu Cys Ala Ile Ser Leu Asp Arg Tyr Trp 100 105 110 gee gtg age cgc gcg ctg gag tae aac tee aag cgc acc eeg cgc cgc 384 Ala Vai Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg 115 120 125 ate aag tgc ate ate etc act gtg tgg etc atc gee gee gtc atc tcg 432 Ile Lys Cys Ile Ile Leu Thr Vai Trp Leu Ile Ala Ala Vai Ile Ser 130 135 140 ctg eeg ccc etc atc tae aag ggc gae cag ggc ccc cag eeg cgc ggg 480 *. \ Leu Pro Pro Leu Ile Tyr Lys Gly Asp Gin Gly Pro Gin Pro Arg Gly ·' 145 150 155 160 • · .· cgc ccc cag tgc aag etc aac cag gag gee tgg tae atc ctg gee tee 528 .*··, Arg Pro Gin Cys Lys Leu Asn Gin Glu Ala Trp Tyr Ile Leu Ala Ser 165 170 175 I 0 ... age ate gga tet ttc ttt get eet tgc etc atc atg atc ett gtc tae 576 Ser Ile Gly Ser Phe Phe Ala Pro Cys Leu Ile Met Ile Leu Vai Tyr 180 185 190 ctg cgc atc tae ctg ate gee aaa cgc age aac cgc aga ggt ccc agg 624 • *· Leu Arg Ile Tyr Leu Ile Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg 195 200 205 .gee aag ggg ggg eet ggg cag ggt gag tee aag cag ccc cga ccc gae 672 ’· ’·’ Ala Lys Gly Gly Pro Gly Gin Gly Glu Ser Lys Gin Pro Arg Pro Asp 210 215 220 cat ggt ggg get ttg gee tea gee aaa ctg cca gee ctg gee tet gtg 720 His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Vai 225 230 235 240 6 114483 get tet gee aga gag gtc aac gga cac teg aag tee act ggg gag aag 768 Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys 245 250 255 gag gag ggg gag acc cct gaa gat act ggg ace egg gee ttg cca ccc 816 Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro 260 265 270 agt tgg get gee ett ccc aac tea ggc cag ggc cag aag gag ggt gtt 864 Ser Trp Ala Ala Leu Pro Asn Ser Gly Gin Gly Gin Lys Glu Gly Val 275 280 285 tgt ggg gca tet cca gag gat gaa get gaa gag gag gaa gag gag gag 912 Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu Glu 290 295 300 gag gag gag gaa gag tgt gaa ccc cag gca gtg cca gtg tet ccg gee 960 Glu Glu Glu Glu Glu Cys Glu Pro Gin Ala Val Pro Val Ser Pro Ala 305 310 315 320 tea get tgc age ccc ccg ctg cag cag cca cag ggc tee egg gtg ctg 1008 Ser Ala Cys Ser Pro Pro Leu Gin Gin Pro Gin Gly Ser Arg Val Leu 325 330 335 gee acc eta cgt ggc cag gtg etc ctg ggc agg ggc gtg ggt get ata 1056 Ala Thr Leu Arg Gly Gin Val Leu Leu Gly Arg Gly Val Gly Ala lie 340 345 350 ggt ggg cag tgg tgg cgt ega egg geg cag ctg acc egg gag aag ege 1104 Gly Gly Gin Trp Trp Arg Arg Arg Ala Gin Leu Thr Arg Glu Lys Arg 355 360 365 : ttc acc ttc gtg ctg get gtg gtc att ggc gtt ttt gtg etc tgc tgg 1152 Phe Thr Phe Val Leu Ala Val Val lie Gly Val Phe Val Leu Cys Trp ·'/·;* 370 375 380 • « · • · • .- ttc ccc ttc ttc ttc age tae age ctg ggc gee ate tgc ccg aag cac 1200 Phe Pro Phe Phe Phe Ser Tyr Ser Leu Gly Ala lie Cys Pro Lys His *·*·" 385 390 395 400 • · ... tgc aag gtg ccc cat ggc etc ttc cag ttc ttc ttc tgg ate ggc tae 1248 '...· Cys Lys Val Pro His Gly Leu Phe Gin Phe Phe Phe Trp lie Gly Tyr 405 410 415 tgc aac age tea ctg aac cct gtt ate tae acc ate ttc aac cag gac 1296 Cys Asn Ser Ser Leu Asn Pro Val lie Tyr Thr lie Phe Asn Gin Asp 420 425 430 : ttc ege cgt gee ttc egg agg ate ctg tgc ege ccg tgg acc cag aeg 1344 Phe Arg Arg Ala Phe Arg Arg lie Leu Cys Arg Pro Trp Thr Gin Thr 435 440 445 gee tgg tga 1353 Ala Trp :"i 450 <210> 4 <211> 450 <212> PRT <213> Homo sapiens 7 114483 <400> 4 Met Asp His Gin Asp Pro Tyr Ser Val Gin Ala Thr Ala Ala lie Ala 15 10 15 Ala Ala lie Thr Phe Leu lie Leu Phe Thr lie Phe Gly Asn Ala Leu 20 25 30 Val lie Leu Ala Val Leu Thr Ser Arg Ser Leu Arg Ala Pro Gin Asn 35 40 45 Leu Phe Leu Val Ser Leu Ala Ala Ala Asp lie Leu Val Ala Thr Leu 50 55 60 lie lie Pro Phe Ser Leu Ala Asn Glu Leu Leu Gly Tyr Trp Tyr Phe 65 70 75 80 Arg Arg Thr Trp Cys Glu Val Tyr Leu Ala Leu Asp Val Leu Phe Cys 85 90 95 Thr Ser Ser lie Val His Leu Cys Ala lie Ser Leu Asp Arg Tyr Trp 100 105 110 Ala Val Ser Arg Ala Leu Glu Tyr Asn Ser Lys Arg Thr Pro Arg Arg 115 120 125 lie Lys Cys lie lie Leu Thr Val Trp Leu lie Ala Ala Val lie Ser 130 135 140 Leu Pro Pro Leu lie Tyr Lys Gly Asp Gin Gly Pro Gin Pro Arg Gly 145 150 155 160 Arg Pro Gin Cys Lys Leu Asn Gin Glu Ala Trp Tyr lie Leu Ala Ser ,.*·*: 165 170 175 • * ’ Ser lie Gly Ser Phe Phe Ala Pro Cys Leu lie Met lie Leu Val Tyr 180 185 190 Leu Arg lie Tyr Leu lie Ala Lys Arg Ser Asn Arg Arg Gly Pro Arg '···’ 195 200 205 • · ... Ala Lys Gly Gly Pro Gly Gin Gly Glu Ser Lys Gin Pro Arg Pro Asp : : 210 215 220 * « * His Gly Gly Ala Leu Ala Ser Ala Lys Leu Pro Ala Leu Ala Ser Val .·. ; 225 230 235 240 Ala Ser Ala Arg Glu Val Asn Gly His Ser Lys Ser Thr Gly Glu Lys ’;· 245 250 255 Glu Glu Gly Glu Thr Pro Glu Asp Thr Gly Thr Arg Ala Leu Pro Pro 260 265 270 Ser Trp Ala Ala Leu Pro Asn Ser Gly Gin Gly Gin Lys Glu Gly Val ·' *’ 275 280 285 Cys Gly Ala Ser Pro Glu Asp Glu Ala Glu Glu Glu Glu Glu Glu Glu 290 295 300 Glu Glu Glu Glu Glu Cys Glu Pro Gin Ala Val Pro Val Ser Pro Ala 305 310 315 320 0 114483 8 Ser Ala Cys Ser Pro Pro Leu Gin Gin Pro Gin Gly Ser Arg Val Leu 325 330 335 Ala Thr Leu Arg Gly Gin Val Leu Leu Gly Arg Gly Val Gly Ala lie 340 345 350 Gly Gly Gin Trp Trp Arg Arg Arg Ala Gin Leu Thr Arg Glu Lys Arg 355 360 365 Phe Thr Phe Val Leu Ala Val Val lie Gly Val Phe Val Leu Cys Trp 370 375 380 Phe Pro Phe Phe Phe Ser Tyr Ser Leu Gly Ala lie Cys Pro Lys His 385 390 395 400 Cys Lys Val Pro His Gly Leu Phe Gin Phe Phe Phe Trp lie Gly Tyr 405 410 415 Cys Asn Ser Ser Leu Asn Pro Val lie Tyr Thr lie Phe Asn Gin Asp 420 425 430 Phe Arg Arg Ala Phe Arg Arg lie Leu Cys Arg Pro Trp Thr Gin Thr 435 440 445 Ala Trp 450 <210> 5 <211> 19 <212> DNA <213> Artificial Sequence \ <220> ·/·· <223> Description of Artificial Sequence: PCR primer pair I < · ·' V <400> 5 ggggcgacgc tcttgtcta 19 • I <210> 6 <211> 19 <212> DNA <213> Artificial Sequence ’ ’·* <220> * » < ‘ : <223> Description of Artificial Sequence: PCR primer pair <400> 6 ggtctccccc tcctccttc 19 <210> 7 !v: <211> 18 ’ <212> DNA ·“> <213> Artificial Sequence <220> <223> Description of Artificial Sequence: PCR primer pair <400> 7 gcagcaaccg cagaggtc 18 9 114483 <210> 8 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: PCR primer pair <400> 8 gggcaagaag cagggtgac 19 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <22 0> <223> Description of Artificial Sequence: PCR primer pair <400> 9 agggtgtttg tggggcatct 20 <210> 10 <211> 21 <212> DNA <213> Artificial Sequence <22 0> <223> Description of Artificial Sequence: PCR primer pair • 1 • · · <400> 10 ·, ·· caagctgagg ccggagacac t 21 • · t · « « * 1 1 1 1 * · ’ 1 · • I ’ 1 1 • 1 • 1 • 1 I t
FI20010323A 2001-02-20 2001-02-20 Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta FI114483B (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI20010323A FI114483B (sv) 2001-02-20 2001-02-20 Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta
AU2002231847A AU2002231847A1 (en) 2001-02-20 2002-02-13 Method for detecting a risk of hypertension and uses thereof
CNA028086015A CN1522303A (zh) 2001-02-20 2002-02-13 检测高血压危险因素的方法及其应用
DE0001368454T DE02711915T1 (de) 2001-02-20 2002-02-13 Verfahren zum nachweis eines bluthochdruckrisikos und verwendungen davon
EP02711915A EP1368454A1 (en) 2001-02-20 2002-02-13 Method for detecting a risk of hypertension and uses thereof
JP2002566324A JP2004528830A (ja) 2001-02-20 2002-02-13 高血圧症発症の危険度の判定方法とその用途
PCT/FI2002/000113 WO2002066617A1 (en) 2001-02-20 2002-02-13 Method for detecting a risk of hypertension and uses thereof
US10/077,870 US7029849B2 (en) 2001-02-20 2002-02-20 Method for detecting a risk of hypertension and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010323A FI114483B (sv) 2001-02-20 2001-02-20 Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta
FI20010323 2001-02-20

Publications (3)

Publication Number Publication Date
FI20010323A0 FI20010323A0 (sv) 2001-02-20
FI20010323A FI20010323A (sv) 2002-08-21
FI114483B true FI114483B (sv) 2004-10-29

Family

ID=8560429

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20010323A FI114483B (sv) 2001-02-20 2001-02-20 Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta

Country Status (8)

Country Link
US (1) US7029849B2 (sv)
EP (1) EP1368454A1 (sv)
JP (1) JP2004528830A (sv)
CN (1) CN1522303A (sv)
AU (1) AU2002231847A1 (sv)
DE (1) DE02711915T1 (sv)
FI (1) FI114483B (sv)
WO (1) WO2002066617A1 (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI117516B (sv) * 2002-12-11 2006-11-15 Jurilab Ltd Oy Förfarande och reagensförpackning för att upptäcka risken för diabetes
US20050209289A1 (en) * 2004-03-16 2005-09-22 Talarico Matthew T Method for vascular dysregulation
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20060211684A1 (en) * 2005-01-13 2006-09-21 Perlegen Sciences, Inc. Use of alpha-2 adrenergic receptor agonists
US20080269346A1 (en) * 2005-02-17 2008-10-30 University Of Florida Research Foundation, Inc. B-Blocker Pharmacogenetics in Heart Failure
US20090270474A1 (en) * 2005-12-06 2009-10-29 Keiichi Shibagaki Therapeutic Agent for Keratoconjunctival Disorder
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
CN108948183B (zh) * 2018-06-05 2022-01-28 武汉华纪元生物技术开发有限公司 α1受体和AT1受体抗原类似物多肽及其抗体检测试剂盒和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053337A (en) 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
EP1071710B2 (en) * 1998-04-15 2011-11-02 Merck Serono Biodevelopment Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
WO2001029082A1 (en) * 1999-10-22 2001-04-26 Oy Juvantia Pharma Ltd A DNA MOLECULE ENCODING A VARIANT α2B-ADRENOCEPTOR PROTEIN, AND USES THEREOF

Also Published As

Publication number Publication date
WO2002066617A8 (en) 2003-11-27
FI20010323A0 (sv) 2001-02-20
CN1522303A (zh) 2004-08-18
WO2002066617A1 (en) 2002-08-29
EP1368454A1 (en) 2003-12-10
US20030003470A1 (en) 2003-01-02
DE02711915T1 (de) 2004-07-08
FI20010323A (sv) 2002-08-21
AU2002231847A1 (en) 2002-09-04
US7029849B2 (en) 2006-04-18
JP2004528830A (ja) 2004-09-24

Similar Documents

Publication Publication Date Title
Saeed et al. Genetic variants in LEP, LEPR, and MC4R explain 30% of severe obesity in children from a consanguineous population
US20180148786A1 (en) Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
US6521747B2 (en) Haplotypes of the AGTR1 gene
US20150051114A1 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
US20030092013A1 (en) Diagnosis and treatment of vascular disease
US20230287502A1 (en) Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Variants And Uses Thereof
Maekawa et al. Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population
FI114483B (sv) Förfarande för att påvisa en risk för förhöjt blodtryck och användningar av detta
US20040091912A1 (en) Diagnostic method
US7939257B2 (en) Polymorphic GHSR nucleic acids and uses thereof
JP2001520021A (ja) βアドレナリン受容体多型
US20080020385A1 (en) Use Of A Genetic Modification In The Human Gnaq Gene For Predicting Risk Of Disease, The Course Of Disease, And Reaction To Treatments
US20040152637A1 (en) DNA molecule encoding a variant alpha-2B-adrenoaceptor protein and uses thereof
US6861217B1 (en) Variation in drug response related to polymorphisms in the β2-adrenergic receptor
EP2129801B1 (en) Tbc1d1 as a diagnostic marker for obesity or diabetes
US20060154249A1 (en) Method and kit for detecting a risk for diabetes or a metabolic syndrome
US20090228995A1 (en) Polymorphisms and Haplotypes of the Alpha 2C Adrenergic Receptor Gene
JP4659620B2 (ja) 糖尿病又は糖尿病性腎症の治療又は予防薬のスクリーニング方法
WO2000031307A1 (en) POLYMORPHISMS IN THE 5&#39; LEADER CISTRON OF THE β2-ADRENERGIC RECEPTOR
JP2000316578A (ja) 糖尿病発症危険因子の検出方法
US20030165902A1 (en) Haplotypes of the F2R gene
US20030194728A1 (en) Haplotypes of the SLC26A2 gene
US20030198969A1 (en) Haplotypes of the TACR2 gene
US20030165844A1 (en) Haplotypes of the TNFRSF1A gene
BR122024015811A2 (pt) Uso de um anticorpo anti-il-6 para o tratamento de doença cardiovascular

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114483

Country of ref document: FI